Brokerages Set Pulmonx Co. (NASDAQ:LUNG) Price Target at $12.75

Pulmonx Co. (NASDAQ:LUNG - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six brokerages that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $12.75.

LUNG has been the topic of a number of analyst reports. Stifel Nicolaus reduced their price target on Pulmonx from $17.00 to $16.00 and set a "buy" rating on the stock in a research report on Thursday, October 31st. Citigroup reiterated a "neutral" rating and issued a $7.50 target price (down from $17.00) on shares of Pulmonx in a report on Wednesday, December 11th. Finally, Wells Fargo & Company lowered their price target on shares of Pulmonx from $10.00 to $8.00 and set an "equal weight" rating for the company in a report on Wednesday, December 11th.

Pulmonx Trading Up 4.2 %

NASDAQ LUNG traded up $0.27 during trading hours on Friday, reaching $6.76. The company's stock had a trading volume of 788,217 shares, compared to its average volume of 296,620. The firm has a fifty day simple moving average of $6.55 and a 200-day simple moving average of $6.87. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77. Pulmonx has a 52 week low of $5.46 and a 52 week high of $14.84. The stock has a market cap of $266.94 million, a P/E ratio of -4.60 and a beta of 0.66.

Pulmonx (NASDAQ:LUNG - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.07. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%. The firm had revenue of $20.39 million during the quarter, compared to the consensus estimate of $20.39 million. During the same quarter last year, the firm earned ($0.39) earnings per share. Equities analysts forecast that Pulmonx will post -1.53 earnings per share for the current fiscal year.

Insider Buying and Selling at Pulmonx

In other news, Director Glendon E. French III sold 20,000 shares of the company's stock in a transaction dated Thursday, October 17th. The shares were sold at an average price of $6.52, for a total transaction of $130,400.00. Following the transaction, the director now owns 1,091,974 shares in the company, valued at approximately $7,119,670.48. This represents a 1.80 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel David Aaron Lehman sold 5,497 shares of the firm's stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $6.19, for a total value of $34,026.43. Following the completion of the sale, the general counsel now owns 197,851 shares of the company's stock, valued at approximately $1,224,697.69. This represents a 2.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 49,873 shares of company stock valued at $324,070. 5.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Pulmonx

A number of institutional investors and hedge funds have recently made changes to their positions in LUNG. 272 Capital LP bought a new stake in Pulmonx in the 3rd quarter worth about $25,000. nVerses Capital LLC bought a new position in shares of Pulmonx in the third quarter valued at approximately $26,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Pulmonx during the second quarter valued at approximately $37,000. Hsbc Holdings PLC bought a new stake in Pulmonx during the second quarter worth $93,000. Finally, Mackenzie Financial Corp purchased a new position in Pulmonx in the second quarter worth $102,000. Institutional investors and hedge funds own 91.04% of the company's stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.